While POLQ inhibitors have not been explored in PCa to our knowledge, they may be valuable reagents to investigate for future combination therapy approaches involving NHEJ (DNA-PKcs inhibitors), PARP inhibitors, RT, or ICB, as well as mutations in selected DDR genes. The gene discussed is POLQ; the disease is posterior cortical atrophy.